A detailed history of Maryland Capital Management transactions in Amgen Inc stock. As of the latest transaction made, Maryland Capital Management holds 5,796 shares of AMGN stock, worth $1.85 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
5,796
Previous 3,296 75.85%
Holding current value
$1.85 Million
Previous $802,000 62.84%
% of portfolio
0.11%
Previous 0.06%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$224.46 - $253.15 $561,150 - $632,875
2,500 Added 75.85%
5,796 $1.31 Million
Q2 2022

Aug 11, 2022

SELL
$230.71 - $256.74 $34,837 - $38,767
-151 Reduced 4.38%
3,296 $802,000
Q1 2022

May 12, 2022

SELL
$219.27 - $242.57 $83,541 - $92,419
-381 Reduced 9.95%
3,447 $834,000
Q4 2021

Feb 11, 2022

SELL
$198.88 - $227.6 $35,997 - $41,195
-181 Reduced 4.51%
3,828 $861,000
Q3 2021

Nov 12, 2021

BUY
$212.27 - $248.7 $7,217 - $8,455
34 Added 0.86%
4,009 $852,000
Q2 2021

Aug 13, 2021

BUY
$233.58 - $259.14 $17,518 - $19,435
75 Added 1.92%
3,975 $969,000
Q1 2021

May 11, 2021

SELL
$221.91 - $258.6 $4,438 - $5,172
-20 Reduced 0.51%
3,900 $970,000
Q4 2020

Feb 11, 2021

SELL
$216.38 - $257.67 $46,738 - $55,656
-216 Reduced 5.22%
3,920 $901,000
Q3 2020

Nov 12, 2020

SELL
$234.65 - $260.95 $65,702 - $73,066
-280 Reduced 6.34%
4,136 $1.05 Million
Q2 2020

Aug 12, 2020

BUY
$197.81 - $242.74 $133,917 - $164,334
677 Added 18.11%
4,416 $1.04 Million
Q1 2020

May 13, 2020

BUY
$182.24 - $241.7 $481,660 - $638,813
2,643 Added 241.15%
3,739 $758,000
Q4 2019

Feb 11, 2020

BUY
$189.21 - $243.2 $207,374 - $266,547
1,096 New
1,096 $264,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $171B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Maryland Capital Management Portfolio

Follow Maryland Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maryland Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Maryland Capital Management with notifications on news.